Welcome!

News Feed Item

Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund Complete Calendar Year 2013 as WSJ Category Kings

BOSTON, MA -- (Marketwired) -- 01/21/14 -- The Eventide Gilead Fund's no-load share class (NASDAQ: ETGLX) and the Eventide Healthcare & Life Sciences Fund's no-load share class (NASDAQ: ETNHX) were both named as "Category Kings" by the Wall Street Journal for the one-year period ending December 31, 2013, in recognition of ranking within the top 10 funds in their categories (Midcap Growth and Health & Biotech, respectively) for total returns. The Eventide Gilead Fund finished the year ranked #3 out of 412 funds, and the Eventide Healthcare & Life Sciences Fund ranked #6 out of 87 funds.

The Eventide Funds are managed by Eventide Asset Management, LLC, a Boston-based investment advisor that practices values-based investing. For Eventide, values-based investing is a form of investing that seeks to partner with companies that create real value and blessing for their customers, employees, and other stakeholders. "We are pleased with the outperformance of both funds during the past year, as well as since the inception of these funds. We interpret the results as evidence that the principle of service above profits can potentially create reciprocal blessings for businesses and their shareholders," said Eventide's CEO, Robin John. "We strongly believe that value creation is the key indicator of business vitality and a reliable leading indicator of financial performance."

The Eventide Gilead Fund achieved a one-year total return of 52.93%, compared with the Russell Mid-Cap Growth Index return of 35.74% and S&P 500 Index return of 32.39%, outperforming each by 17.19% and 20.54%, respectively. The Eventide Healthcare & Life Sciences Fund achieved a one-year total return of 62.01%, compared with the Healthcare Blended Index return of 51.11% and S&P 500 Index return of 32.39%, outperforming each by 10.9% and 29.62%, respectively.

The following table outlines the Eventide Gilead Fund's performance since inception:

                                                                  Since
                                                                inception
                                    3 year         5 year      (7/08/2008)
                                  annualized     annualized     annualized
As of 12/31/2013 1 year return      return         return         return
---------------- -------------  -------------  -------------  -------------
Eventide Gilead
 Fund*                   52.93%         21.90%         25.67%         17.75%
---------------- -------------  -------------  -------------  -------------
S&P 500 Total
 Return Index            32.39%         16.18%         17.94%          9.43%
---------------- -------------  -------------  -------------  -------------
Russell Mid-Cap
 Growth Total
 Return Index            35.74%         15.63%         23.37%         10.89%
---------------- -------------  -------------  -------------  -------------

The following table outlines the Eventide Healthcare & Life Science Fund's performance since inception:

                                                            Since inception
                                                              (12/27/2012)
                                                               annualized
As of 12/31/2013          3 months return   1 year return        return
------------------------- ---------------  ---------------  ---------------
Eventide Healthcare &
 Life Sciences Fund*                 3.37%           62.01%           61.65%
------------------------- ---------------  ---------------  ---------------
S&P 500 Total Return
 Index                              10.51%           32.39%           32.74%
------------------------- ---------------  ---------------  ---------------
Healthcare Blended Index            10.89%           51.11%           51.23%
------------------------- ---------------  ---------------  ---------------

Three-year and inception returns are annualized. The performance data quoted here represents past performance. Current performance may be lower or higher than the performance data quoted above. Past performance is no guarantee of future results. The investment return and principal value of an investment will fluctuate so that investor's shares, when redeemed, may be worth more or less than their original cost. Please review the funds' prospectus for more information regarding the funds' fees and expenses. Performance shown is for No-load Class shares (please see a prospectus for information about other share classes). For performance information current to the most recent month-end, please call toll-free 877-771-EVEN (3836).

Eventide Gilead Fund Expenses ratios: Gross Expenses 1.75%; Net Expenses 1.64%. The advisor has agreed to maintain the Fund's total annual operating expenses (excluding certain fees and expenses) at 1.42% at least until October 31, 2014.

Eventide Healthcare & Life Sciences Fund Expenses ratios: Gross Expenses 9.51%; Net Expenses 1.64%. The advisor has agreed to maintain the Fund's total annual operating expenses (excluding certain fees and expenses) at 1.43% at least until October 31, 2014.

As of 12/31/2013, the Eventide Gilead Fund had $323,576,279.67 in net assets and the Eventide Healthcare & Life Sciences Fund had $39,745,499.32 in net assets.

Wall Street Journal rankings are not intended to constitute investment advice. As a result, you should not make an investment decision on the basis of this information. Rather, you should use the rankings for informational purposes only.

The S&P 500 is an index created by Standard & Poor's Corp considered to represent the performance of the stock market generally. The Russell Midcap Growth Index measures the performance of the U.S. equity mid-cap growth segment. It includes mid-cap companies with higher price-to-book ratios and forecasted growth. The Healthcare Blended Index is composed of equal parts of the S&P 400 Healthcare Index and the S&P 600 Healthcare Index. These indexes are not investment products available for purchase.

Mutual Funds involve risk including the possible loss of principal. The Eventide Funds can invest in smaller-sized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies. The Funds' ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria. The funds can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The funds can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The funds can have risk associated with a higher portfolio turnover, which could result in higher transactional costs. The recent growth rate in the stock market has helped to produce short-term returns that are not typical and may not continue in the future. Because of ongoing market volatility, fund performance may be subject to substantial short-term changes. An investor should consider the Funds' investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information about Eventide Funds can be found in the Funds' prospectus. Please read the prospectus carefully before investing. To obtain a current prospectus please call the fund, toll free at 877-771-EVEN (3836).

Eventide Funds is distributed by Northern Lights Distributors, LLC, member FINRA, which is not affiliated with Eventide Asset Management, LLC.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Fund Contact:
Jason Myhre
877-771-EVEN (3836)

0195-NLD-1/14/2014

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
"As we've gone out into the public cloud we've seen that over time we may have lost a few things - we've lost control, we've given up cost to a certain extent, and then security, flexibility," explained Steve Conner, VP of Sales at Cloudistics,in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We provide IoT solutions. We provide the most compatible solutions for many applications. Our solutions are industry agnostic and also protocol agnostic," explained Richard Han, Head of Sales and Marketing and Engineering at Systena America, in this SYS-CON.tv interview at @ThingsExpo, held June 6-8, 2017, at the Javits Center in New York City, NY.
DX World EXPO, LLC., a Lighthouse Point, Florida-based startup trade show producer and the creator of "DXWorldEXPO® - Digital Transformation Conference & Expo" has announced its executive management team. The team is headed by Levent Selamoglu, who has been named CEO. "Now is the time for a truly global DX event, to bring together the leading minds from the technology world in a conversation about Digital Transformation," he said in making the announcement.
"We are focused on SAP running in the clouds, to make this super easy because we believe in the tremendous value of those powerful worlds - SAP and the cloud," explained Frank Stienhans, CTO of Ocean9, Inc., in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"Peak 10 is a hybrid infrastructure provider across the nation. We are in the thick of things when it comes to hybrid IT," explained , Chief Technology Officer at Peak 10, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"DX encompasses the continuing technology revolution, and is addressing society's most important issues throughout the entire $78 trillion 21st-century global economy," said Roger Strukhoff, Conference Chair. "DX World Expo has organized these issues along 10 tracks with more than 150 of the world's top speakers coming to Istanbul to help change the world."
"I think DevOps is now a rambunctious teenager – it’s starting to get a mind of its own, wanting to get its own things but it still needs some adult supervision," explained Thomas Hooker, VP of marketing at CollabNet, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We are still a relatively small software house and we are focusing on certain industries like FinTech, med tech, energy and utilities. We help our customers with their digital transformation," noted Piotr Stawinski, Founder and CEO of EARP Integration, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We've been engaging with a lot of customers including Panasonic, we've been involved with Cisco and now we're working with the U.S. government - the Department of Homeland Security," explained Peter Jung, Chief Product Officer at Pulzze Systems, in this SYS-CON.tv interview at @ThingsExpo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We're here to tell the world about our cloud-scale infrastructure that we have at Juniper combined with the world-class security that we put into the cloud," explained Lisa Guess, VP of Systems Engineering at Juniper Networks, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"I will be talking about ChatOps and ChatOps as a way to solve some problems in the DevOps space," explained Himanshu Chhetri, CTO of Addteq, in this SYS-CON.tv interview at @DevOpsSummit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Your homes and cars can be automated and self-serviced. Why can't your storage? From simply asking questions to analyze and troubleshoot your infrastructure, to provisioning storage with snapshots, recovery and replication, your wildest sci-fi dream has come true. In his session at @DevOpsSummit at 20th Cloud Expo, Dan Florea, Director of Product Management at Tintri, provided a ChatOps demo where you can talk to your storage and manage it from anywhere, through Slack and similar services with...
The financial services market is one of the most data-driven industries in the world, yet it’s bogged down by legacy CPU technologies that simply can’t keep up with the task of querying and visualizing billions of records. In his session at 20th Cloud Expo, Karthik Lalithraj, a Principal Solutions Architect at Kinetica, discussed how the advent of advanced in-database analytics on the GPU makes it possible to run sophisticated data science workloads on the same database that is housing the rich...
SYS-CON Events announced today that Massive Networks will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Massive Networks mission is simple. To help your business operate seamlessly with fast, reliable, and secure internet and network solutions. Improve your customer's experience with outstanding connections to your cloud.
"We are an IT services solution provider and we sell software to support those solutions. Our focus and key areas are around security, enterprise monitoring, and continuous delivery optimization," noted John Balsavage, President of A&I Solutions, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.